RITUXIMAB
Manufacturer: Genentech, Inc.
Score: 144.0
Rituxan (RITUXIMAB) is a monoclonal antibody used to treat various conditions, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris. It works by targeting the CD20 antigen on B cells, leading to their depletion. The drug has shown efficacy in several clinical trials, but it also carries important safety information, including warnings about fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Dosing recommendations vary by condition, and special population considerations include use during pregnancy, nursing, pediatric use, and geriatric use.
Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy
Dose adjustments may be necessary based on individual patient response and tolerability
375 mg/m^2 as an intravenous infusion
375 mg/m^2 as an intravenous infusion for pediatric patients aged 6 months and older
375 mg/m^2 on the day prior to the initiation of FC chemotherapy, then 500 mg/m^2 on Day 1 of cycles 2-6
Not established
Two 1000 mg intravenous infusions separated by 2 weeks
Not established
375 mg/m^2 once weekly for 4 weeks
375 mg/m^2 once weekly for 4 weeks for pediatric patients aged 2 years and older
Two 1000 mg intravenous infusions separated by 2 weeks
Not established